Immunis Welcomes UC Berkeley Professor Irina Conboy to the Scientific Advisory Board

2023-09-28

高管变更免疫疗法

IRVINE, Calif.--(BUSINESS WIRE)-- Immunis, Inc., a private biotech company creating novel cellular secretome therapies for age and disease-related immune decline, is delighted to have Professor Irina Conboy on its Scientific Advisory Board. Dr. Conboy is a Professor of Bioengineering at UC Berkeley, investigator at the Quantitative Biology Institute, and Editor in Chief of Rejuvenation Research. Her groundbreaking studies have unveiled critical paradigms on the effects of age-related and pathological changes on tissue maintenance and repair, setting the stage for novel therapeutic interventions. A Stanford Ph.D. graduate, Dr. Conboy is a renowned secretome researcher that has consistently been at the forefront of groundbreaking advancements in biotech. Her expertise ranges from novel bio-computation and biological age quantification to cutting-edge CRISPR strategies for diagnosing and treating tissue degeneration. She has received several awards from esteemed organizations including the W.M. Keck Foundation, Calico, SENS Research Foundation, and Life Extension Foundation to name a few. It’s no surprise that her numerous U.S. invention patents and impressive publications have been recognized by accredited news outlets like The Economist, Science Daily, and TIME Magazine. As a scientific advisor to Juvena Therapeutics, NovaXS biotech companies, and The Alliance for Longevity Initiative (a4li) nonprofit, Dr. Conboy is nothing short of a leader in her field. Dr. Conboy shared that she “was introduced to the Immunis team by Dr. Hanadie Yousef, CEO of Juvena, and one of [her] most talented former students.” She’s enthusiastic about her role as Scientific Advisor and hopes to “contribute to Immunis' quest of making enhanced healthspan a therapeutic reality through regenerative secretomes.” Undoubtedly, Dr. Conboy’s unparalleled insights and innovative methodologies will guide Immunis closer to its mission of developing transformative secretome therapies. About Immunis Inc. Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: Cautionary Note Regarding Forward-Looking Statements This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein. View source version on businesswire.com: Contacts contact@immunisbiomedical.com Source: Immunis, Inc. View this news release online at: